Abstract A41: TRICEPS: A feasibility study of personalized targeted therapy in relapsed/refractory childhood cancers

2016 ◽  
Author(s):  
Sylvie Langlois ◽  
Jasmine Healy ◽  
Mathieu Lajoie ◽  
Sophie Dumoucel ◽  
Fida Khater ◽  
...  
Keyword(s):  
Targeted Therapy ◽  
Feasibility Study ◽  
Childhood Cancers

Bone-targeted therapy in advanced androgen-independent prostate carcinoma: A feasibility study

2005 ◽  
Vol 23 (16_suppl) ◽  
pp. 4793-4793
Author(s):  
A. Crespo ◽  
M. Sureda ◽  
B. Vazquez ◽  
J. Rebollo ◽  
E. Calvo ◽  
...  
Keyword(s):  
Targeted Therapy ◽  
Feasibility Study ◽  
Prostate Carcinoma ◽  
Androgen Independent

scholarly journals Fusion Oncoproteins in Childhood Cancers: Potential Role in Targeted Therapy

2021 ◽  
Vol 26 (6) ◽  
pp. 541-555
Author(s):  
Sara D. A. Angione ◽  
Alemayehu Y. Akalu ◽  
Jessica Gartrell ◽  
Elimika Pfuma Fletcher ◽  
Gilbert J. Burckart ◽  
...  
Keyword(s):  
Targeted Therapy ◽  
Molecular Genetics ◽  
Cause Of Death ◽  
Scientific Knowledge ◽  
Targeted Therapies ◽  
Potential Role ◽  
Chromosomal Rearrangements ◽  
Childhood Cancers ◽  
Pediatric Cancers ◽  
Pediatric Sarcomas

Cancer remains the leading cause of death from disease in children. Historically, in contrast to their adult counterparts, the causes of pediatric malignancies have remained largely unknown, with most pediatric cancers displaying low mutational burdens. Research related to molecular genetics in pediatric cancers is advancing our understanding of potential drivers of tumorigenesis and opening new opportunities for targeted therapies. One such area is fusion oncoproteins, which are a product of chromosomal rearrangements resulting in the fusion of different genes. They have been identified as oncogenic drivers in several sarcomas and leukemias. Continued advancement in the understanding of the biology of fusion oncoproteins will contribute to the discovery and development of new therapies for childhood cancers. Here we review the current scientific knowledge on fusion oncoproteins, focusing on pediatric sarcomas and hematologic cancers, and highlight the challenges and current efforts in developing drugs to target fusion oncoproteins.

Sign in / Sign up

Export Citation Format

Share Document